Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Strober B, Coates LC, Lebwohl MG, Deodhar A, Leibowitz E, Rowland K, Kollmeier AP, Miller M, Wang Y, Li S, Chakravarty SD, Chan D, Shawi M, Yang YW, Thaҫi D, Rahman P. Strober B, et al. Among authors: chakravarty sd. Drug Saf. 2024 Jan;47(1):39-57. doi: 10.1007/s40264-023-01361-w. Epub 2023 Oct 31. Drug Saf. 2024. PMID: 37906417 Free PMC article. Clinical Trial.
Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Chakravarty SD, Xu XL, Subramanian RA, Agarwal P, Sheng S, Jiang Y, Zhou B, Zhuang Y, van der Heijde D, Mease PJ. McInnes IB, et al. Among authors: chakravarty sd. Arthritis Rheumatol. 2021 Apr;73(4):604-616. doi: 10.1002/art.41553. Epub 2021 Mar 17. Arthritis Rheumatol. 2021. PMID: 33043600 Free PMC article. Clinical Trial.
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
Ritchlin CT, Helliwell PS, Boehncke WH, Soriano ER, Hsia EC, Kollmeier AP, Chakravarty SD, Zazzetti F, Subramanian RA, Xu XL, Zuraw QC, Sheng S, Jiang Y, Agarwal P, Zhou B, Zhuang Y, Shawi M, Karyekar CS, Deodhar A. Ritchlin CT, et al. Among authors: chakravarty sd. RMD Open. 2021 Feb;7(1):e001457. doi: 10.1136/rmdopen-2020-001457. RMD Open. 2021. PMID: 33568556 Free PMC article. Clinical Trial.
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.
Mease PJ, McInnes IB, Tam LS, Eaton K, Peterson S, Schubert A, Chakravarty SD, Parackal A, Karyekar CS, Nair S, Boehncke WH, Ritchlin C. Mease PJ, et al. Among authors: chakravarty sd. Rheumatology (Oxford). 2021 May 14;60(5):2109-2121. doi: 10.1093/rheumatology/keab119. Rheumatology (Oxford). 2021. PMID: 33844022 Free PMC article.
Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020.
Orbai AM, Reddy SM, Dennis N, Villacorta R, Peterson S, Mesana L, Chakravarty SD, Lin I, Karyekar CS, Wang Y, Pacou M, Walsh J. Orbai AM, et al. Among authors: chakravarty sd. Clin Rheumatol. 2021 Dec;40(12):4933-4942. doi: 10.1007/s10067-021-05839-9. Epub 2021 Jul 21. Clin Rheumatol. 2021. PMID: 34287723 Free PMC article.
75 results